Ibogaine Success Rate Evidence: What Counts as Success?

Two clinics can both say "our success rate is supported by published research" and mean completely different things. The ibogaine success rate evidence that exists today comes from a small number of observational studies, one open-label detoxification series, one retrospective survey and one recent academic study in veterans. Each of them defined "success" in its own way, measured it with its own instruments, and checked at its own point in time.

Before any percentage can mean anything to you, you need to know what was counted, when, and how. That is the whole subject of this article.

Why does ibogaine success rate evidence vary so much?

The first reason is definitional. "Success" after ibogaine can mean at least four different things: completing detoxification without transitioning to an opioid replacement medication, using less of the substance at a follow-up point, being fully abstinent at a specific month, or functioning better in daily life. The same group of patients can produce a very different number depending on which of these is chosen.

The second reason is size. The two published twelve-month observational studies of ibogaine for opioid use disorder are small. Brown and Alper followed 30 participants treated in Mexico; Noller and colleagues followed 14 participants treated in New Zealand, where ibogaine can be prescribed by authorised physicians under a non-approved medicine framework.

Both appeared in the American Journal of Drug and Alcohol Abuse in 2018. With cohorts that size, a change of two or three people shifts the headline percentage by a wide margin.

The third reason is that none of these studies were designed to produce a marketing figure. They were designed to describe what happened to a specific group of people under specific conditions. If you are new to the compound, start with a plain explanation of what is ibogaine and how it is thought to act, then come back to the outcome question with that grounding.

What outcomes do ibogaine studies actually measure?

Every published ibogaine study reports on one or more of the following outcome families. Knowing which family a number belongs to is the single most useful skill when reading a success claim.

Withdrawal severity and detox completion

The earliest and most consistent finding in the literature concerns the acute detox window. Studies use standardised scales for opioid withdrawal, such as the Subjective Opiate Withdrawal Scale, to score symptoms before and after dosing. The open-label detoxification series published by Mash and colleagues in Frontiers in Pharmacology in 2018 is organised around this phase: withdrawal and craving measured during the inpatient stay, with outcomes reported as change on those scales.

A claim like "patients completed detox" is usually drawn from this kind of measurement. It says something real, but it says nothing about month six. Detox completion is also the outcome most likely to be reported by clinics themselves, because it is observable before the patient leaves the building.

Substance use at follow-up

The two 2018 observational studies used the Addiction Severity Index, a structured interview that captures drug use and related problems over a recent window, and repeated it at scheduled follow-ups across a year. A "success rate" derived from this kind of data might describe people who were abstinent at the final interview, people who reduced their use compared with baseline, or people who never returned to use at any point. Those are three different populations and three different numbers.

Craving, mood and self-rated functioning

Several studies added mood and craving measures, for example the Beck Depression Inventory in the New Zealand cohort. The retrospective survey by Davis and colleagues, published in the Journal of Psychedelic Studies in 2017, asked people who had already undergone ibogaine treatment to rate its effectiveness and describe their current psychological functioning. Survey data of this type is useful for understanding the lived experience of treatment, but it depends entirely on who chose to respond.

Disability and daily functioning

The 2024 Stanford study by Cherian and colleagues in Nature Medicine treated 30 Special Operations veterans with traumatic brain injury using magnesium-ibogaine, and it shows how an academic protocol builds an endpoint. The prespecified primary outcome was disability measured on the World Health Organization Disability Assessment Schedule 2.0 at one month, alongside clinician-rated scales for PTSD, depression and anxiety. This was not an addiction study, but it illustrates the standard the field is moving toward: one primary endpoint, named in advance, rated by a clinician rather than the patient.

Self-reported or verified? How the outcome was collected

Two studies can measure the same thing and still not be comparable, because the method of collection changes what the number means.

Most ibogaine follow-up data is self-reported, gathered by telephone or in-person interview. Self-report is a legitimate research method, but it has known weaknesses in substance use research, and biochemical verification such as urine toxicology is uncommon in the ibogaine literature. When a published paper reports abstinence, check whether the word "verified" appears anywhere near it. When a clinic reports abstinence, ask the same question.

Then look at the denominator. If 30 people were treated and 18 could be reached at twelve months, a "success rate" calculated from those 18 is not the same as one calculated from all 30. Researchers describe this as loss to follow-up, and the honest papers report it plainly. Clinic marketing almost never does.

Consider, too, who was in the study to begin with. People who travel abroad for ibogaine and pass a cardiac screen are not a random sample of everyone with an opioid use disorder. They tend to be motivated, medically cleared and able to fund travel and treatment.

Researchers call this selection bias, and it means that even a perfectly measured outcome in a study cohort may not transfer to a different population. It is not a flaw in the studies; it is a limit on how far their numbers travel.

Finally, remember that safety events are outcomes too. The New Zealand observational study reported one participant death during the study period. Any account of ibogaine success rate evidence that leaves adverse events out of the ledger is presenting half the data.

Can ibogaine success rates be compared with other addiction treatments?

Marketing copy often places an ibogaine percentage next to a figure for methadone, buprenorphine or residential rehab and lets the reader draw the obvious conclusion. The comparison rarely holds up, because the treatments are measured against different constructs.

Trials of maintenance medications for opioid use disorder frequently use retention in treatment as a primary or key secondary outcome: how many people are still taking the medication and attending appointments at a given month. That is a sensible metric for a therapy that works only while you keep taking it. It is a meaningless metric for ibogaine, which is typically given once or over a few days and then stopped. An ibogaine study cannot report retention, so it reports something else, and the two numbers end up side by side as if they measured the same thing.

Residential programmes present a different mismatch. Many report completion rates, meaning the share of people who finished the programme, which says nothing about what happened after discharge. Set a completion figure beside a twelve-month abstinence figure and you are comparing a process measure with an outcome measure.

There is also the question of what "relapse" means across settings. In a maintenance trial, use of the prescribed medication is not relapse. In an ibogaine cohort, a return to any opioid, including a prescribed one, may be counted as failure, or may not, depending on the paper. Until two studies define their terms identically, their percentages are not comparable, and no responsible clinician would claim otherwise.

Point-in-time or continuous: why the timing of the measurement matters

Even within the "substance use at follow-up" family, two very different questions hide behind the word "abstinent." The first is point-prevalence abstinence: was the person using at the moment of the twelve-month interview? The second is continuous abstinence: did the person avoid use at every point between treatment and the twelve-month interview? The first number is always higher than the second for the same cohort, sometimes dramatically so.

Regulators evaluating approved medications for opioid use disorder have tended to favour responder definitions built on repeated negative drug screens across a multi-week window, precisely because a single snapshot can flatter a treatment. Ibogaine research has not yet been held to that standard. When you read a percentage, ask whether it is a snapshot or a stretch of time. The comprehensive ibogaine guide on this site walks through the published follow-up studies individually if you want to see how each one handled the question.

What will the registered trials measure, and how should you read a number today?

As of this writing, no completed, published, randomised placebo-controlled trial of ibogaine for opioid use disorder exists. That gap is beginning to close. Texas committed public funding to ibogaine clinical research in 2025, and academic groups are registering protocols that will be required to name a primary endpoint before the first participant is dosed. Expect those endpoints to look like the Stanford design: a single prespecified measure, a fixed assessment window, and either clinician rating or biochemical verification rather than a phone call.

Until that evidence arrives, the most useful thing you can do with any ibogaine success rate is interrogate it with four questions:

• What was defined as success? Detox completion, reduced use, abstinence or functioning.
• When was it measured? During treatment, at one month, at twelve months; as a snapshot or continuously.
• How was it collected? Self-report or verified.
• Who is in the denominator? Everyone treated, or only those who answered the phone.

A number that survives all four questions is worth your attention. A number that cannot answer even one of them is a slogan.

The ibogaine success rate evidence available today is real but limited, and it is far more honest than the percentages typically attached to it. For a neutral, clinic-independent overview of the research, safety screening and treatment process, start with the ibogaine treatment guide home page and work through the research section at your own pace.

This article is for educational purposes and does not constitute medical advice. Ibogaine carries serious cardiac and other risks and is not approved by the FDA for any indication. Anyone considering treatment should consult a qualified physician.